KRAS and neoplasm: In particular, we will discuss how our understanding of tumour cell-intrinsic KRAS signalling and PD-L1 expression has evolved in relation to anti-tumour immunity and mechanisms of immune escape, and how this is driving innovation in research and clinical settings.